Clinical Trial Update: Ablation of Oligometastasis Combined With Lenvatinib and PD-1 Inhibitor for Advanced Hepatocellular Carcinoma [NA]

View source ↗

Summary

Clinical trial assessing the combination of ablation of oligometastasis, lenvatinib, and a PD-1 inhibitor for advanced hepatocellular carcinoma is currently rec…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• LENVIMA (lenvatinib)
• PD-1 inhibitor (unspecified)

Snippet

Sponsor: Sun Yat-sen University | Conditions: Advanced Hepatocellular Carcinoma, Oligometastasis | NA | Status: RECRUITING